HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Skin ulcerative defects therapy in chronic venous insufficiency

DOI: https://doi.org/10.29296/25877305-2023-08-15

L. Sakaniya(1, 2), Candidate of Medical Sciences, A. Chekh(1); Professor
I. Korsunskaya(2), MD
1-Moscow Research and Practical Center of Dermatovenereology
and Cosmetology, Moscow Healthcare Department
2-Center for Theoretical Problems of Physicochemical Pharmacology,
Russian Academy of Sciences, Moscow

Chronic venous insufficiency (CVI) is characterized by various symptoms and manifestations, including skin manifestations, among which venous eczema is the most common – about 44% of patients. The itching associated with eczema leads to scratching, which in turn increases the chances of secondary infections. In addition, venous ulceration of the lower extremities often develops in CVI, which can also be complicated by secondary infection, making the choice of therapy difficult. The treatment of venous eczema uses combined glucocorticosteroids, which relieve pruritus and infectious complications, as well as care products with a pronounced moisturizing effect. In the presence of ulcerative defects it is necessary to use means for cleansing of the wound surface and acceleration of epithelization processes.

chronic venous insufficiency
varicose eczema
varicose ulcers

  1. Matić M., Matić A., Gajinov Z. et al. Major risk factors for chronic venous disease development in women: is childbirth among them? Women Health. 2019; 59 (10): 1118–27. DOI: 10.1080/03630242.2019.1590492
  2. Lacroix P., Aboyans V., Preux P.M. et al. Epidemiology of venous insufficiency in an occupational population. Int Angiol. 2003; 22 (2): 172–6.
  3. Branisteanu D.E., Feodor T., Baila S. et al. Impact of chronic venous disease on quality of life: Results of vein alarm study. Exp Ther Med. 2019; 17 (2): 1091–6. DOI: 10.3892/etm.2018.7054
  4. Serra R., Buffone G., de Franciscis A. et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg. 2012; 26 (5): 636–42. DOI: 10.1016/j.avsg.2011.11.036
  5. Serra R., Grande R., Butrico L. et al. Epidemiology, diagnosis and treatment of chronic venous disease: A systematic review. Chirurgia. 2016; 29: 34–45.
  6. Serra R., Grande R., Buffone G. et al. Chronic venous disease is more aggressive in patients with varicocele. Acta Phlebol. 2013; 14 (2): 57–60.
  7. Beebe-Dimmer J.L., Pfeifer J.R., Engle J.S. et al. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005; 15 (3): 175–84. DOI: 10.1016/j.annepidem.2004.05.015
  8. Serra R., Butrico L., Ruggiero M. et al. Epidemiology, diagnosis and treatment of chronic leg ulcers: a systematic review. Acta Phlebol. 2015; 16: 9–18.
  9. de Franciscis S., Nobile C.G.A., Larosa E. et al. Air contamination in the sclerosing foam for the treatment of varicose veins. Phlebology. 2016; 31 (2): 96–100. DOI: 10.1177/0268355514565194
  10. Eklöf B., Rutherford R.B., Bergan J.J. et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40 (6): 1248–52. DOI: 10.1016/j.jvs.2004.09.027
  11. Rabe E., Pannier F. Clinical, aetiological, anatomical and pathological classification (CEAP): gold standard and limits. Phlebology. 2012; 27 (Suppl 1): 114–8. DOI: 10.1258/phleb.2012.012s19
  12. Serra R., Buffone G., Costanzo G. et al. Altered Metalloproteinase-9 expression as the least common denominator between varicocele, inguinal hernia and chronic venous disorders. Ann Vasc Surg. 2014; 28 (3): 705–9. DOI: 10.1016/j.avsg.2013.07.026
  13. Amato B., Coretti G., Compagna R. et al. Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J. 2015; 12 (6): 641–5. DOI: 10.1111/iwj.12181
  14. Serra R., Buffone G., Falcone D. et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen. 2013; 21 (3): 395–401. DOI: 10.1111/wrr.12035
  15. Tracz E., Zamojska E., Modrzejewski A. et al. Quality of life in patients with venous stasis ulcers and others with advanced venous insufficiency. Holist Nurs Pract. 2015; 29 (2): 96–102. DOI: 10.1097/HNP.0000000000000072
  16. Yao P.Y., Mukhdomi T. Varicose Vein Treatment: Endovenous Laser Therapy. 2023 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
  17. Rzepecki A.K., Blasiak R. Stasis dermatitis: differentiation from other common causes of lower leg inflammation and management strategies. Curr Geriat Rep. 2018; 7 (4): 222–7. DOI: 10.1007/s13670-018-0257-x
  18. Sundaresan S., Migden M.R., Silapunt S. Stasis dermatitis: pathophysiology, evaluation, and management. Am J Clin Dermatol. 2017; 18 (3): 383–90. DOI: 10.1007/s40257-016-0250-0
  19. Theodosat A. Skin diseases of the lower extremities in the elderly. Dermatol Clin. 2004; 22 (1): 13–21. DOI: 10.1016/S0733-8635(03)00113-X
  20. Payne D. Venous eczema: more than just a rash. Br J Community Nurs. 2023; 28 (6): 298–300. DOI: 10.12968/bjcn.2023.28.6.298
  21. Kirkup M.E. Xerosis and stasis dermatitis. Preventive Dermatology. London: Springer, 2011; p. 71–9.
  22. Heilesen B. Studies on the therapeutic effect of trypsin. J Invest Dermatol. 1954; 23 (1): 7–15. DOI: 10.1038/jid.1954.77
  23. Воронина Т.А. Мексидол, основные эффекты, механизм действия, применение. М., 2004; с. 21 [oronina T.A. Meksidol, osnovnye effekty, mekhanizm deistviya, primenenie. M., 2004; р. 21 (in Russ.)].
  24. Çakici N., Fakkel T.M., van Neck J.W. et al. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016; 33 (11): 1466–76. DOI: 10.1111/dme.13083